Table I.
Drug concentration | |||||
---|---|---|---|---|---|
MA (mg/ml) | CPT-11 (µg/ml) | OD value | Inhibition rate (%) | q-value | Drug-drug interaction |
0 | 0 | 1.221±0.053 | 0 | ||
0.25 | 0 | 1.072±0.086 | 12.20a | ||
0.5 | 0 | 0.892±0.078 | 26.95a | ||
1 | 0 | 0.783±0.025 | 35.87a | ||
2 | 0 | 0.575±0.034 | 52.91a | ||
0 | 1.25 | 0.942±0.063 | 22.85a | ||
0 | 2.5 | 0.765±0.051 | 37.35a | ||
0 | 5 | 0.553±0.027 | 54.71a | ||
0 | 10 | 0.497±0.016 | 59.29a | ||
0.25 | 1.25 | 0.841±0.025 | 31.08a,b | 0.96 | Sum |
0.5 | 2.5 | 0.522±0.042 | 57.25a,b | 1.06 | Sum |
1 | 5 | 0.151±0.012 | 87.61a,b | 1.23 | Synergistic |
2 | 10 | 0.057±0.007 | 95.29a,b | 1.19 | Synergistic |
P<0.01, compared with normal control
P<0.01, compared with individual drug treatment alone at the same dose. MA, matrine; CPT-11, irinotecan.